BioRestorative Therapies Completes Patient Enrollment In Its Phase 2 Trial Of BRTX-100 For Chronic Lumbar Disc Disease
Benzinga Newsdesk 9 months ago
Health CareGeneral
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective,
- Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease
- The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placebo
- Prospective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical design
- Enrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing